Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02228382 · ClinicalTrials.gov registry record · Phase 4
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
A Phase 4 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 163
- Enrollment target
NCT02228382 is a Phase 4 study that was terminated before completion, run by Pfizer. The registered enrollment target is 163 participants.
The verdict
NCT02228382, a Phase 4 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 163 participants
- Enrollment target
Study Summary
The purpose of this study is to fulfill the post-authorization commitment made by Pfizer to the European Medicines Agency in providing additional safety and efficacy data in approximately 150 Philadelphia Chromosome Positive Chronic Myeloid Leukemia patients with high unmet medical need, including 75 Chronic Phase, Accelerated Phase or Blast Phase patients in the fourth or later line treatment setting (i.e., after treatment with at least 3 other Tyrosine Kinase Inhibitors).
Interventions
- DRUG Bosutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2014-11-07 |
| Est. Completion | 2020-10-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02228382
The ClinicalTrials.gov registry entry for NCT02228382 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bosutinib is the first listed.
NCT02228382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02228382 about?
NCT02228382 is a clinical study titled "Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors". The purpose of this study is to fulfill the post-authorization commitment made by Pfizer to the European Medicines Agency in providing additional safety and efficacy data in approximately 150 Philadelphia Chromosome Positive Chronic Myeloid Leukemia patients with high unmet medical need, including 7...
What is the current status of trial NCT02228382?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 163 participants. The study started on 2014-11-07. Estimated completion is 2020-10-13.
What interventions are being tested in trial NCT02228382?
The interventions under investigation include: Bosutinib (DRUG).
Who is sponsoring clinical trial NCT02228382?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.